Aflibercept clinical trials
Also written Eylea, Zaltrap, VEGF Trap and AVE0005.
How each study uses aflibercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the aflibercept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Nov 2011 · EYLEA · BLA 125387 (FDA, Drugs@FDA)
- European Union
- 21 Nov 2012 · Eylea · EMEA/H/C/002392 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
266 studies that test it; most in 2013 (28)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 11 |
| 2007 | 15 |
| 2008 | 7 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 21 |
| 2013 | 28 |
| 2014 | 27 |
| 2015 | 27 |
| 2016 | 22 |
| 2017 | 16 |
| 2018 | 13 |
| 2019 | 14 |
| 2020 | 10 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 9 |
| 2025 | 4 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 87 · Other 180
Regeneron Pharmaceuticals (25) · Bayer (22) · Sanofi (20) · National Cancer Institute (NCI) (18) · Unity Health Toronto (4) · Kim's Eye Hospital (3) · Singapore National Eye Centre (3) · Amgen (3)
Often tested with
Tested in the same studies.
Ranibizumab (14) · Bevacizumab (5) · FOLFIRI-Ziv-aflibercept Regimen (4) · FOLFIRI Regimen (4) · Docetaxel (3) · Fluorouracil (2) · Capecitabine (2) · Verteporfin (2)
Related medicines
As reviewed, each with the page that says it.
- One of Angiogenesis inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 25 phase 3 studies under way
Aflibercept is the comparator. A study of two new drugs counts under both.
- 4Vorolanib · EyePoint Pharmaceuticals, Inc. · next primary completion Oct 2027
- 3OLN324 · Ollin Biosciences, Inc. · next primary completion Dec 2028
- 2Axitinib · Ocular Therapeutix, Inc. · next primary completion Jan 2027
- 2EYE201 · EyeBiotech Ltd. · next primary completion Jun 2028
- 2RC28-E protein · RemeGen Co., Ltd.
- 1Tarcocimab tedromer · Kodiak Sciences Inc
- 1IBI302 · Innovent Biologics (Suzhou) Co. Ltd. · next primary completion Feb 2027
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test aflibercept, phase 3 first.
- Jul 2027A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationPhase 3 · Amgen
- Jun 2027Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMDNot applicable · Berner Augenklinik
- Sep 2027Mean Visual Acuity Changes Following Five Injections of AfliberceptNot applicable · McMaster University
Studies
Open first, then newest update. How each study uses aflibercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 267
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationRecruitingPhase 3AmgenNCT07614776Written as ABP 938 8 mg
- VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyNot yet recruitingPhase 2University of MiamiNCT07891182Written as Aflibercept Injection
- A Study to Compare GNR-139 and Eylea® in Patients With nAMDRecruitingPhase 3AO GENERIUMNCT07844148Written as aflibercept
- Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD PatientsNot yet recruitingEarly Phase 1Tianjin Medical University Eye HospitalNCT07728981Written as Aflibercept 8mg
- Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS TrialRecruitingPhase 3Yeungnam University College of MedicineNCT07389980Written as aflibercept 8 mg
- Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular EdemaEnrolling by invitationNot applicableCMH Multan Institute of Medical SciencesNCT07338097Written as Aflibercept (2.0 mg)
- Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract SurgeryNot yet recruitingPhase 4Ahmad Zeeshan JamilNCT07301775Written as Aflibercept (Eylea)
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06121180Written as ZIV-Aflibercept
- Aflibercept and Bevacizumab for Diabetic MaculopathiesRecruitingPhase 4Al-Mustansiriyah UniversityNCT06850571Written as Aflibercept 2Mg/0.05Ml Inj,Oph
- High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyRecruitingPhase 4Retina Consultants of Orange CountyNCT06662994Written as Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Plasma Biomarker for Aflibercept in Advanced Colorectal CancerRecruitingPhase 4Yonsei UniversityNCT04810585Written as Aflibercept + FOLFIRI
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02298959Written as Ziv-Aflibercept
- Macular Vascular Density After Aflibercept or Ranibizumab Treatment for Diabetic Macular EdemaCompletedPhase 4Benha UniversityNCT07924072Written as Aflibercept
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyActive, not recruitingPhase 2AbbVieNCT05296447Written as Aflibercept
- A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular DegenerationCompletedPhase 4BayerNCT06591598Written as Aflibercept (BAY86-5321, Eylea)
- Aflibercept After Ranibizumab in Exudative Age-related Macular DegenerationCompletedPhase 3Centre Hospitalier Intercommunal CreteilNCT02157077Written as Aflibercept
- Mean Visual Acuity Changes Following Five Injections of AfliberceptActive, not recruitingNot applicableMcMaster UniversityNCT02645266Written as Aflibercept Injection [Eylea]
- A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular OedemaCompletedPhase 2Samsung Bioepis Co., Ltd.NCT07844343Written as SB15 PFS
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)Active, not recruitingPhase 3Regeneron PharmaceuticalsNCT06491914Written as Aflibercept 8 mg
- Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous TreatmentCompletedPhase 4Kim's Eye HospitalNCT06683950Written as Aflibercept 8mg
See all 267 studies that test aflibercept →
Given beside what is tested · 52 — aflibercept is usual care or a partner of the new treatment
- A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVORecruitingPhase 2EyeBiotech Ltd.NCT07205887Written as Aflibercept 2.0 mg
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)RecruitingPhase 3Adverum Biotechnologies, Inc.NCT07482176Written as Aflibercept
- Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCTRecruitingNot applicableZhongshan Ophthalmic Center, Sun Yat-sen UniversityNCT06610747Written as Aflibercept 2Mg/0.05Ml Inj,Oph
- Adjunct Episcleral Brachytherapy for PCVNot yet recruitingPhase 3Salutaris Medical Devices, Inc.NCT05251636Written as Aflibercept Injection
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaActive, not recruitingPhase 2Kyowa Kirin Co., Ltd.NCT06116916Written as Aflibercept Injection
- Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationCompletedPhase 2Kyowa Kirin Co., Ltd.NCT06116890Written as Aflibercept Injection
- DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DMECompletedPhase 3Jaeb Center for Health ResearchNCT03321513Written as intravitreous aflibercept
- Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)Active, not recruitingPhase 1/2Alcon ResearchNCT05769153Written as Aflibercept Injection
- Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular EdemaCompletedPhase 4The Cleveland ClinicNCT04411693Written as Aflibercept
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular EdemaCompletedPhase 1/2Genentech, Inc.NCT06850922Written as Aflibercept
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationActive, not recruitingPhase 3Adverum Biotechnologies, Inc.NCT06856577Written as Aflibercept
- Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the EyeCompletedPhase 3BayerNCT04423718Written as Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
- Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)CompletedPhase 2Unity Biotechnology, Inc.NCT06011798Written as Aflibercept
- ADVM-022 Intravitreal Gene Therapy for DMECompletedPhase 2Adverum Biotechnologies, Inc.NCT04418427Written as Aflibercept
- Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular DegenerationCompletedPhase 4Medical University of GrazNCT05941715Written as Aflibercept 40 MG/ML
- A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular EdemaCompletedPhase 1/2Opthea LimitedNCT03397264Written as Aflibercept
- Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMDTerminatedPhase 2IVERIC bio, Inc.NCT05571267Written as Eylea
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedPhase 2Ophthotech CorporationNCT02387957Written as aflibercept
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein OcclusionCompletedPhase 3Hoffmann-La RocheNCT04740931Written as Aflibercept
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein OcclusionCompletedPhase 3Hoffmann-La RocheNCT04740905Written as Aflibercept
Showing 20 of 52.
As the comparator · 90 — what is tested is compared with aflibercept
- A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyRecruitingPhase 2Boehringer IngelheimNCT06321302Written as Aflibercept (Eylea®) - US only
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07705607Written as Aflibercept
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07705555Written as Aflibercept
- A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).RecruitingPhase 34D Molecular TherapeuticsNCT07867080Written as EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular DegenerationNot yet recruitingPhase 2Everest Medicines (China) Co.,Ltd.NCT07798375Written as Aflibercept (Eylea)
- Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular DegenerationRecruitingPhase 2AiViva BioPharma, Inc.NCT07557121Written as EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTORecruitingPhase 3Kodiak Sciences IncNCT07734844Written as Aflibercept (2.0 mg)
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationRecruitingPhase 34D Molecular TherapeuticsNCT07064759Written as EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)RecruitingPhase 2/3EyeBiotech Ltd.NCT07440225Written as Aflibercept
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)Not yet recruitingPhase 3Ollin Biosciences, Inc.NCT07841899Written as Aflibercept
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)Not yet recruitingPhase 3Ollin Biosciences, Inc.NCT07842016Written as Aflibercept
- Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)Not yet recruitingPhase 3Ollin Biosciences, Inc.NCT07816315Written as Aflibercept
- Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular DegenerationRecruitingPhase 2West China HospitalNCT07776522Written as Aflibercept (2.0 mg)
- Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)RecruitingPhase 3Innostellar Biotherapeutics Co.,LtdNCT07317934Written as Aflibercept
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)RecruitingPhase 2/3EyeBiotech Ltd.NCT07496567Written as Aflibercept
- Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular EdemaRecruitingPhase 3Alvotech Swiss AGNCT07489131Written as Eylea HD (aflibercept HD)
- A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular DegenerationNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07489586Written as Aflibercept 8 mg
- Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMDRecruitingPhase 1/2Sinocelltech Ltd.NCT06672536Written as EYLEA 2 MG
- Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)RecruitingPhase 2Sierra Eye AssociatesNCT06942520Written as Aflibercept (2.0 mg)
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDNot yet recruitingPhase 2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06839339Written as Aflibercept
Showing 20 of 90.
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Newly registered2
- Macular Vascular Density After Aflibercept or Ranibizumab Treatment for Diabetic Macular EdemaNov 9, 2026NCT07924072
- VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyOct 23, 2026NCT07891182
Codes
What other systems call aflibercept · ClinicalTrials.gg INT005352
- MeSH (NLM) C533178afliberceptConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 15C2VL427DAFLIBERCEPTConfirmed FDA, NLM
- RxNorm 1304475One source FDA
- NCI Thesaurus C2682Ziv-AfliberceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533178 | aflibercept | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 15C2VL427D | AFLIBERCEPT | Confirmed FDA, NLM |
| RxNorm | 1304475 | — | One source FDA |
| NCI Thesaurus | C2682 | Ziv-Aflibercept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.